1. Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity
   V. Sibaud et al, 2016, Clinical and Experimental Dermatology CrossRef
2. Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein
   Tamio Okimoto et al, 2018, Oncotarget CrossRef
3. Osimertinib-Induced Cutaneous Vasculitis Responsive to Low-Dose Dapsone Without Interruption of Anticancer Therapy: A Case Report and Review of the Literature
   Christopher Iriarte et al, 2022, JTO Clinical and Research Reports CrossRef
4. Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy?
   Giovanni Brandi et al, 2013, Cutaneous and Ocular Toxicology CrossRef
5. Cutaneous Vasculitis Induced by Osimertinib
   Kazuki Hamada et al, 2019, Journal of Thoracic Oncology CrossRef
6. Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: A case report and review of the literature
   Gyula Fekete et al, 2018, Experimental and Therapeutic Medicine CrossRef
7. A Case of Leukocytoclastic Vasculitis Occurred during Combination Chemotherapy of Cetuximab and Paclitaxel
   Yohei YASUTOMI et al, 2020, Nishi Nihon Hifuka CrossRef